Valneva SE (VALN) Profit After Tax (2021 - 2026)
Valneva SE (VALN) posted Profit After Tax of $37.5 million for Q1 2026, up 164.48% sequentially from -$58.2 million in Q4 2025, and up 286.67% YoY from $9.7 million in Q1 2025.
Analysis
Valneva SE (VALN) Profit After Tax (2021 - 2026) Analysis & Trends
Valneva SE has reported Profit After Tax for 6 years, with the latest figure at $37.5 million in Q1 2026.
- Quarterly Profit After Tax rose 286.67% year-over-year to $37.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.0 million (up 32.61% YoY) and the FY2025 annual result came in at -$134.1 million, down 911.65% from the prior year.
- Profit After Tax improved to $37.5 million in Q1 2026 per VALN's latest filing, from -$58.2 million in the prior quarter.
- Over five years, Profit After Tax peaked at $155.2 million in Q2 2022 and troughed at -$247.3 million in Q4 2022.
- A 5-year average of -$22.2 million and a median of -$10.1 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2025 and 2026: Profit After Tax sank 651.16% in 2025, then soared 286.67% in 2026.
- Over 5 years, Profit After Tax stood at -$247.3 million in 2022, then gained by 25.72% to -$183.7 million in 2023, then jumped by 78.51% to -$39.5 million in 2024, then plunged by 47.52% to -$58.2 million in 2025, then jumped by 164.48% to $37.5 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $37.5 million, -$58.2 million, and -$76.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Valneva SE | 584.00 Mn | 442.75 Mn | 1.86 Mn | -36.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.27 Mn |
| Mar 31, 2026 | -37.55 Mn |
| Dec 31, 2025 | -58.20 Mn |
| Sep 30, 2025 | -51.89 Mn |
| Jun 30, 2025 | -13.11 Mn |
| Mar 31, 2025 | -9.71 Mn |
| Dec 31, 2024 | -39.43 Mn |
| Sep 30, 2024 | -10.19 Mn |
| Jun 30, 2024 | -26.85 Mn |
| Mar 31, 2024 | 64.00 Mn |
| Dec 31, 2023 | -34.60 Mn |
| Sep 30, 2023 | -37.26 Mn |
| Jun 30, 2023 | -18.42 Mn |
| Mar 31, 2023 | -19.46 Mn |
| Dec 31, 2022 | -45.10 Mn |
| Sep 30, 2022 | 73.02 Mn |
| Jun 30, 2022 | -210.78 Mn |
| Mar 31, 2022 | 29.23 Mn |
| Dec 31, 2021 | -365.34 Mn |
| Sep 30, 2021 | 391.91 Mn |